Диссертация (1139554), страница 56
Текст из файла (страница 56)
2009; 21(2): 233-240.325. Rosenberg S.A., Lotze M.T., Muul L.M. et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin2 to patients with metastatic cancer. // New Eng J Med. 1985; 313: 1485-1492.326. Rosenberg S.A., Restifo N.P., Yang J.C. et al. Adoptive cell transfer: a clinical pathto effective cancer immunotherapy. // Nature Rev Cancer. 2008; 8: 299-308.327.
Rosental B., Brusilovsky M., Hadad U. et al. Proliferating cell nuclear antigen is anovel inhibitory ligand for the natural cytotoxicity receptor NKp44. // Immunology.2011; 187: 5693-5702.328. Rouce R., Shaim H., Sekine T. et al. The TGF-β/SMAD pathway is an importantmechanism for NK cell immune evasion in childhood B acute lymphoblastic leukemia. // Leukemia. 2016; 30(4): 800-811.329. Rubnitz J.E., Inaba H. NKAML: a pilot study to determine the safety and feasibilityof haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. // Clinical Oncology.
2010; 28(6): 955-959.330. Ruggeri L., Aversa F., Martelli M.F., Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. // Immunological Reviews.2006; 214: 202-218.331. Rusakiewicz S., Semeraro M., Sarabi M. et al.
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. // Cancer Research. 2013; 73(12):3499–3510.288332. Sabel M.S., Su G., Griffith K.A., Chang A.E. Intratumoral delivery of encapsulatedIL- 12, IL-18 and TNF-alpha in a model of metastatic breast cancer. // Breast CancerRes. Treat.
2010. 122(2): 325-336.333. Sabry M., Lowdell M.W. Tumor-primed NK cells: waiting for the green light. //Frontiers in Immunology. 2013; 4(408): 1-7.334. Said E.A., Dupuy F.P., Trautmann L. et al. Programmed death-1-induced interleukin10 production by monocytes impairs CD4+ T cell activation during HIV infection.2010. // Nat. Med. 16 (4): 452-459.335. Sakamoto N., Ishikawa T., Kokura S. et al.
Phase I clinical trial of autologous NKcell therapy using novel expansion method in patients with advanced digestive cancer. // J Transl Med. 2015; 13: 277.336. Salih H.R., Antropius H., Gieseke F. et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. // Blood. 2003; 102:1389-1396.337. Salih H.R., Goehlsdorf D., Steinle A. Release of MICB molecules by tumor cells:mechanism and sMICB in sera of cancer patients // Hum Imm. 2006; 67: 188-5.338.
Salih H.R., Rammensee H.G., Steinle A. Cutting edge: down-regulation of MICA onhuman tumors by proteolytic shedding. // Immunology. 2002; 169: 4098-4102.339. Sandoval-Montes C., Santos-Argumedo L. CD38 is expressed selectively during theactivation of a subset of mature T-cells with redused proliferation but improved potential to produce cytokines. // Leukocyte Biology.
2005; 77: 513-521.340. Sangiolo D., Martinuzzi E., Todorovic M., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. // Int Imm. 2008; 20(7): 841848.341. Schadendorf D., Ugurel S., Schuler-Thurner B. et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment ofpatients with metastatic melanoma: a randomized phase III trial of the DC studygroup of the DeCOG.
// Ann. Oncol. 2006; 17: 563-570.342. Schmidt-Wolf I.G.H., Negrin R.S., Kiem H.-P., et al. Use of a SCID mouse/humanlymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell289activity. // Experimental Medicine. 1991; 174(1): 139-149.343. Serebrovskaya E.O., Edelweiss E.F., Stremovskiy O.A., Lukyanov K.A., ChudakovD.M., Deyev S.M. Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein.
// Proc. Natl. Acad. Sci. USA. 2009; 106: 9221-9225.344. Shinoda K., Tokoyoda K., Hanazawa A., et al. Type II membrane protein CD69 regulates the formation of resting T-helper memory. // PNAS. 2012; 109(19): 74097414.345. Sliwkowski M.X., Mellman I. Antibody therapeutics in cancer // Science. 2013; 341:1192-8346. Society A.C. Cancer Facts and Figures. 2013, American Cancer Society, Atlanta, Ga,USA, 2013.347. Steidl C., Lee T., Shah S.P. et al. Tumor-associated macrophages and survival inclassic Hodgkin’s lymphoma. // New Eng J of Medicine. 2010; 362: 875-885.348. Steinle A., Li P., Morris D.L.
et al. Interactions of human NKG2D with its ligandsMICA, MICB, and homologs of the mouse RAE-1 protein family. // Immunogenetics. 2001; 53: 279-287.349. Stern M., Passweg J.R., Meyer-Monard S. et al. Pre-emptive immunotherapy withpurified natural killer cells after haploidentical SCT: a prospective phase II study intwo centers.
// Bone Marrow Transplantation. 2013; 48: 433-438.350. Stetson D.B., Medzhitov R. Type I interferons in host defense. // Immunity. 2006;25: 373-381.351. Stringaris K., Sekine T., Khoder A., et al. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. // Haematologica. 2014; 99(5): 836-847.352. Sullivan J.L., Byron K.S., Brewster F.E., Purtilo D.T. Deficient natural killer cell activity in x-linked lymphoproliferative syndrome. // Science. 1980; 210(4469): 543-5.353. Sun J.C., Beilke J.N., Lanier L.L. Adaptive immune features of natural killer cells. //Nature.
2009; 457(7229): 557-561.354. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insightsand future prospects. // Internal Medicine. 2009; 266(2): 154-181.290355. Tamaki S., Sanefuzi N., Kawakami M.
et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. // HumanImmunology. 2008; 69: 88-93.356. Tarazona R., Duran E., Solana R. Natural killer cell recognition of melanoma: newclues for a more effective immunotherapy. Frontiers in Immunology. 2015; 6: 649.357. Tarek N., Le Luduec J.B., Gallagher M.M.
et al. Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. // Clin Invest. 2012; 122: 3260-70.358. Terme M., Ullrich E., Delahaye N.F., Chaput N., Zitvogel L. Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
// NatureImmunology. 2008; 9(5): 486-494.359. Terunuma H., Deng Х., Nishino N., Watanabe K. NK cells-based autologous immune enhancement therapy for cancer. // JSRM. 2013: 9(1): 9-13.360. Thiery J., Keefe D., Boulant S. et al. Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells. // NatureImmunology. 2011; 12(8): 770-777.361.
Todaro M., Orlando V., Cicero G. et al. Chemotherapy Sensitizes Colon Cancer Initiating Cells to Vc9Vd2 T Cell-Mediated Cytotoxicity. // PLOS ONE. 2013; 1-8.362. Tomblyn M. Radioimmunotherapy for B-cell non-hodgkin lymphomas. // CancerControl. 2012; 19 (3):196-203.363. Travers P., Walport M., Shlomchik.
M.J. The Immune System in Health and Science.Immuno-Biology 6-th edition, Garland Science Publishing. 2005; 27.364. Trinchieri G. Biology of natural killer cells. // Adv Immunol. 1989; 47: 187-376.365. Tseng H.C., Bui V., Man Y.G., Cacalano N., Jewett A. Induction of split anergy conditions natural killer cells to promote differentiation of stem cells through cell-cellcontact and secreted factors. // Frontiers in Immunology. 2014; 5: 269.366. Ullrich E., Koch J., Cerwenka A., Steinle A.
New prospects on theNKG2D/NKG2DL system for oncology. // Oncoimmunology. 2013 Oct 1; 2(10):e26097.367. Vacca P., Vitale C., Montaldo E., et al. CD34+ hematopoietic precursors are presentin human decidua and differentiate into natural killer cells upon interaction with stromal cells. // PNAS. 2011; 108: 2402-2407.291368. Valteau-Couanet D., Leboulaire C., Maincent K. et al. Dendritic cells for NK/LAKactivation: rationale for multicellular immunotherapy in neuroblastoma patients. //Blood. 2002; 100: 2554-2561.369. Van der Vliet H.J., Balk S.P., Exley M.A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
